Limits...
Early versus late intravitreal triamcinolone acetonide for macular edema associated with branch retinal vein occlusion.

Oh JY, Seo JH, Ahn JK, Heo JW, Chung H - Korean J Ophthalmol (2007)

Bottom Line: Best-corrected visual acuity and foveal thickness by optical coherence tomography were measured 1, 3, and 6 months post-injection.In patients that received treatment after a disease duration of <or= 3 months, visual acuity and foveal thickness significantly improved from baseline over 6 months of follow-up.However, in those with a duration of >3 months, improvements in visual acuity and foveal thickness, though apparent at 1 month, were not maintained at 3 and 6 months post-triamcinolone.

View Article: PubMed Central - PubMed

Affiliation: Department of Ophthalmology, Seoul National University College of Medicine, Chongno-gu, Seoul, Korea.

ABSTRACT

Purpose: To compare the effect of early versus late intravitreal injection of triamcinolone in patients with macular edema due to branch retinal vein occlusion (BRVO).

Methods: Twenty eyes of 20 patients with macular edema from BRVO, including 10 with duration after onset of or

Results: In patients that received treatment after a disease duration of 3 months, improvements in visual acuity and foveal thickness, though apparent at 1 month, were not maintained at 3 and 6 months post-triamcinolone.

Conclusions: Intravitreal triamcinolone is more effective in patients with BRVO who are treated earlier.

Show MeSH

Related in: MedlinePlus

LogMAR visual acuity results in the early and late treatment groups. A significant sustained improvement was evident in the early treatment group throughout the subsequent 6-month follow-up, but in the late treatment group, the initial improvement at 1 month was not sustained at 3 and 6 months.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2629694&req=5

Figure 1: LogMAR visual acuity results in the early and late treatment groups. A significant sustained improvement was evident in the early treatment group throughout the subsequent 6-month follow-up, but in the late treatment group, the initial improvement at 1 month was not sustained at 3 and 6 months.

Mentions: Patient demographics and characteristics of BRVO are shown in Table 1; no statistically significant differences were found between the two groups. In the early treatment group, mean visual acuity significantly improved from a baseline of 1.07±0.45 logMAR units to 0.74±0.51 (p=0.021) at 1 month, 0.63±0.43 (p=0.012) at 3 months, and 0.34±0.33 (p=0.005) at 6 months post-injection. In this group, mean foveal thickness was 666.8±291.7 µm at baseline, and significantly reduced to 233.8±77.2 µm (p<0.001) at 1 month, 351.1±180.8 µm (p=0.026) at 3 months, and 446.2±266.6 µm (p=0.029) at 6 months. However, in the late treatment group, though mean visual acuity significantly improved from baseline 0.80±0.45 to 0.47±0.37 (p=0.039) at 1 month, it did not further improve at 3 months (0.54±0.34, p=0.080) or 6 months (0.60±0.53, p=0.226). Similarly, mean foveal thickness decreased significantly from baseline 597.3±180.1µm to 344.0±183.3 µm (p=0.030) at 1 month, but results did not significantly improve at 3 months (464.0±246.8 µm, p=0.594) or 6 months (545.1±204.6 µm, p=0.952). Comparisons of mean visual acuity and foveal thickness in the two groups are shown in figures 1 and 2, respectively. One patient in the early treatment group and two in the late treatment group experienced an elevated IOP during follow-up, and one in the late treatment group required trabeculectomy.


Early versus late intravitreal triamcinolone acetonide for macular edema associated with branch retinal vein occlusion.

Oh JY, Seo JH, Ahn JK, Heo JW, Chung H - Korean J Ophthalmol (2007)

LogMAR visual acuity results in the early and late treatment groups. A significant sustained improvement was evident in the early treatment group throughout the subsequent 6-month follow-up, but in the late treatment group, the initial improvement at 1 month was not sustained at 3 and 6 months.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2629694&req=5

Figure 1: LogMAR visual acuity results in the early and late treatment groups. A significant sustained improvement was evident in the early treatment group throughout the subsequent 6-month follow-up, but in the late treatment group, the initial improvement at 1 month was not sustained at 3 and 6 months.
Mentions: Patient demographics and characteristics of BRVO are shown in Table 1; no statistically significant differences were found between the two groups. In the early treatment group, mean visual acuity significantly improved from a baseline of 1.07±0.45 logMAR units to 0.74±0.51 (p=0.021) at 1 month, 0.63±0.43 (p=0.012) at 3 months, and 0.34±0.33 (p=0.005) at 6 months post-injection. In this group, mean foveal thickness was 666.8±291.7 µm at baseline, and significantly reduced to 233.8±77.2 µm (p<0.001) at 1 month, 351.1±180.8 µm (p=0.026) at 3 months, and 446.2±266.6 µm (p=0.029) at 6 months. However, in the late treatment group, though mean visual acuity significantly improved from baseline 0.80±0.45 to 0.47±0.37 (p=0.039) at 1 month, it did not further improve at 3 months (0.54±0.34, p=0.080) or 6 months (0.60±0.53, p=0.226). Similarly, mean foveal thickness decreased significantly from baseline 597.3±180.1µm to 344.0±183.3 µm (p=0.030) at 1 month, but results did not significantly improve at 3 months (464.0±246.8 µm, p=0.594) or 6 months (545.1±204.6 µm, p=0.952). Comparisons of mean visual acuity and foveal thickness in the two groups are shown in figures 1 and 2, respectively. One patient in the early treatment group and two in the late treatment group experienced an elevated IOP during follow-up, and one in the late treatment group required trabeculectomy.

Bottom Line: Best-corrected visual acuity and foveal thickness by optical coherence tomography were measured 1, 3, and 6 months post-injection.In patients that received treatment after a disease duration of <or= 3 months, visual acuity and foveal thickness significantly improved from baseline over 6 months of follow-up.However, in those with a duration of >3 months, improvements in visual acuity and foveal thickness, though apparent at 1 month, were not maintained at 3 and 6 months post-triamcinolone.

View Article: PubMed Central - PubMed

Affiliation: Department of Ophthalmology, Seoul National University College of Medicine, Chongno-gu, Seoul, Korea.

ABSTRACT

Purpose: To compare the effect of early versus late intravitreal injection of triamcinolone in patients with macular edema due to branch retinal vein occlusion (BRVO).

Methods: Twenty eyes of 20 patients with macular edema from BRVO, including 10 with duration after onset of or

Results: In patients that received treatment after a disease duration of 3 months, improvements in visual acuity and foveal thickness, though apparent at 1 month, were not maintained at 3 and 6 months post-triamcinolone.

Conclusions: Intravitreal triamcinolone is more effective in patients with BRVO who are treated earlier.

Show MeSH
Related in: MedlinePlus